Abstract
Background & Objective: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.
Results & Conclusion: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.
Keywords: Cariprazine, D3 receptor, bipolar disorder, bipolar mania, bipolar depression, psychiatric disease.
CNS & Neurological Disorders - Drug Targets
Title:Cariprazine in Bipolar Depression and Mania: State of the Art
Volume: 17 Issue: 10
Author(s): Marianna Mazza*, Giuseppe Marano, Gianandrea Traversi, Valentina Carocci, Benedetta Romano and Luigi Janiri
Affiliation:
- Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCSS, Universita Cattolica del Sacro Cuore, Rome,Italy
Keywords: Cariprazine, D3 receptor, bipolar disorder, bipolar mania, bipolar depression, psychiatric disease.
Abstract: Background & Objective: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.
Results & Conclusion: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.
Export Options
About this article
Cite this article as:
Mazza Marianna *, Marano Giuseppe , Traversi Gianandrea , Carocci Valentina, Romano Benedetta and Janiri Luigi , Cariprazine in Bipolar Depression and Mania: State of the Art, CNS & Neurological Disorders - Drug Targets 2018; 17 (10) . https://dx.doi.org/10.2174/1871527317666180828120256
DOI https://dx.doi.org/10.2174/1871527317666180828120256 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Advantages of Nanotechnology- Based Chinese Herb Drugs on Biological Activities
Current Drug Metabolism Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Role of Opioidergic System in Regulating Depression Pathophysiology
Current Pharmaceutical Design Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings
Current Drug Discovery Technologies Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Immunology of VIP: A Review and Therapeutical Perspectives
Current Pharmaceutical Design Chinese Medicine: A Novel Therapeutic Option for Pancreatic Cancer
Current Signal Transduction Therapy New Insights about Regulatory T Cells Distribution and Function with Exercise: The Role of Immunometabolism
Current Pharmaceutical Design Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Iridoid Compound 10-O-trans-p-Coumaroylcatalpol Extends Longevity and Reduces Alpha Synuclein Aggregation in Caenorhabditis elegans
CNS & Neurological Disorders - Drug Targets Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Impairment of Store-operated Calcium Entry: Implications in Alzheimer’s Neurodegeneration
Current Alzheimer Research Next-generation Metabolomics in the Development of New Antidepressants: Using Albiflorin as an Example
Current Pharmaceutical Design GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Genetic Variation in SLCO2B1 is Associated with Serum Levels of Testosterone and its Metabolites Prior to and Two Days after Testosterone Administration
Current Pharmacogenomics and Personalized Medicine Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Conjugative Post-Translational Modifications for Pharmacological Improvement of Therapeutic Proteins
Current Proteomics